Emmaus Life Sciences, Inc. (OTCMKTS:EMMA) Short Interest Up 47.6% in January

Emmaus Life Sciences, Inc. (OTCMKTS:EMMAGet Free Report) saw a large increase in short interest during the month of January. As of January 31st, there was short interest totalling 21,700 shares, an increase of 47.6% from the January 15th total of 14,700 shares. Based on an average daily volume of 20,400 shares, the short-interest ratio is presently 1.1 days.

Emmaus Life Sciences Stock Up 11.8 %

Shares of EMMA stock opened at $0.04 on Friday. The company has a 50 day moving average of $0.02 and a 200-day moving average of $0.02. The firm has a market cap of $2.85 million, a P/E ratio of -0.50 and a beta of 6.64. Emmaus Life Sciences has a 12-month low of $0.00 and a 12-month high of $0.13.

Emmaus Life Sciences Company Profile

(Get Free Report)

Emmaus Life Sciences, Inc, a commercial-stage biopharmaceutical company, discovers, develops, markets, and sells treatments and therapies primarily for rare and orphan diseases in the United States and internationally. The company's lead candidate is Endari, an L-glutamine oral powder to reduce the acute complications of sickle cell disease in adult and pediatric patients five years of age and older.

Read More

Receive News & Ratings for Emmaus Life Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Emmaus Life Sciences and related companies with MarketBeat.com's FREE daily email newsletter.